Background: Regorafenib is an oral diphenyl urea multikinase inhibitor which is anti-angiogenic, and has shown promising anti-tumor activity in Metastatic Colorectal Cancer (mCRC). Reports have shown that response to regorafenib is more favourable in patients with KDR gene mutation. This study correlates KDR gene mutation as an ideal predictive biomarker to regorafenib (Tyrosine Kinase Inhibitor) attempts to correlate response in metastatic colorectal cancer (MCRC).
Abstract:Primary rhabdomyosarcoma (RMS) of breast and RMS, metastatic to breast are rare entities with limited case reports in literature. Here, we report a case of primary rhabdomyosarcoma of breast in an adolescent girl which was metastatic at presentation. She presented with progressively increasing lump in right breast with difficulty in breathing. Histopathology was suggestive of solid variant of alveolar type/embryonal carcinoma (undifferentiated type). Immunohistochemical reports were positive for muscle markers Vimentin and Myf-4, making definitive diagnosis of RMS. Patient had fast progression of disease and died after first cycle of chemotherapy.
The intraperitoneal (IP) administration of antineoplastic agents has been proposed as a method to improve the efficacy of therapy of malignant disease principally confined to the peritoneal cavity especially in carcinoma-ovary. Our patient who had more tumor burden in the peritoneum was refractory to two lines intravenous (IV) chemotherapy who improved on IP administration of platinum and IV nab paclitaxel chemotherapy regime. A 42-year-old lady was diagnosed with stage IV metastatic epithelial ovarian cancer. She suffered from progressive disease on two lines of IV chemotherapy following surgery with persistent rise in serum CA 125 level. Administration of IP platinum and IV nab paclitaxel chemotherapy regime resulted in complete (metabolic/radiological) response with normal CA 125 level. Intraperitoneal chemotherapy can be considered in patients with ovarian cancer with predominantly peritoneal disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.